Allergan has recalled many of its breast implants and tissue expanders due to links to cancer in patients. Defective Allergan breast implants may cause a condition called breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL. On July 24th, 2019, Allergan voluntarily recalled certain models of its textured breast implants and tissue expanders following the release of global safety information by the Food and Drug Administration (FDA).
If you believe you could have BIA-ALCL or another serious condition because of your breast implants, our Southern California breast implant recall lawyers can help. The attorneys from Panish Shea & Boyle LLP and Bentley & More LLP are coming together to help patients adversely affected by the Allergan implant recall. Schedule a free and confidential consultation when you contact us.
The FDA issued a request to Allergan, a global pharmaceutical company, in July to recall its BIOCELL® textured breast implants and breast tissue expanders. The request cited concerns regarding the development of breast implant-associated anaplastic large cell lymphoma from the company’s implants. The request came after the FDA analyzed 573 BIA-ALCL cases worldwide and found a disproportionate number involving Allergan implants. Allergan voluntarily recalled several of its breast implant and expander products.
This list is not exhaustive. The FDA has the full list of recalled products by Allergan on its website. The recall does not apply to smooth BIOCELL® or MICROCELL® breast implants or expander products. The latest Allergan breast implant recall comes about three years after a similar recall in Canada. A safety review by Health Canada found a link between BIA-ALCL and breast implants with textured exteriors, including those by Allergan Inc.
Defective Allergan breast implants and tissue expanders could cause a serious and potentially life-threatening type of cancer. Anaplastic large cell lymphoma is a form of non-Hodgkin’s lymphoma. It is a rare type of cancer that impacts the body’s lymph system. BIA-ALCL specifically refers to anaplastic large cell lymphoma from breast implants – a condition with 573 known cases (including 33 fatalities). The majority (481) of these cases involved patients with Allergan breast implants at the time of their BIA-ALCL diagnoses.
BIA-ALCL is typically not terminal. The development of BIA-ALCL most often occurs in the scar tissues and fluids surrounding the breast implants rather than the breast tissue itself. Removal of the breast implant and surrounding tissues and fluids generally puts a patient in remission. Some patients may need additional chemotherapy treatments to eliminate lymphoma. However, this type of cancer could be deadly if left untreated. The sooner the patient receives a diagnosis, the better the odds are of survival.
If you have Allergan breast implants listed in the recall but have not noticed any symptoms of BIA-ALCL, the FDA is not recommending the removal of your implants. Keep your Allergan breast implants and stay alert for signs of a problem, such as pain, discomfort or swelling at the implant site. You may also notice lumps in your breast or armpit. Patients with BIA-ALCL report symptoms 3 to 14 years after the procedure. See a doctor right away if you notice any symptoms. Then, contact our attorneys for a free case evaluation.
The personal injury, product liability and wrongful death attorneys from two different Southern California law firms are working together to provide premier legal services to victims of the Allergan breast implant recall. We may be able to obtain financial compensation for your physical pain, emotional anguish, related medical bills, lost wages and other damages. Our breast implant recall lawyers are available for free consultations in Los Angeles and Orange Counties. Contact us today.